Preeclampsia complicates 3-5% of all pregnancies. 1 The pathogenesis behind preeclampsia and eclampsia is not completely understood but the theories are based on cerebral vasoconstriction or a vasogenic edema predominately in the parieto-occipital regions of the brain. This is called posterior reversible encephalopathy syndrome. 2 Case studies have shown that a majority of women with eclampsia and some of women with preeclampsia who underwent magnetic resonance tomography had evidence of posterior reversible encephalopathy syndrome. 3, 4 There is also evidence of white matter lesions, months to years after pregnancy in women who experienced eclampsia. 5 Higher mean arterial pressure during pregnancy might have an influence on occurrence of lesions [5] [6] [7] and hypertensive pregnancy disorders are associated with cognitive impairment and brain atrophy decades later. 8 It is hard to predict the neurological outcome on both short-and long-term for women with preeclampsia. The current clinical signs and symtoms lack both sensitivity and specificity. 2, 6 In other diseases affecting the central nervous system (CNS) a wide range of different cerebral biomarkers have been studied out of which neuron-specific enolase (NSE) and S100B are the most promising.
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NSE is a glycolytic enzyme. 9 NSE is a member of the enolase family and consists of the γγ homodimer and the αγ heterodimer. [10] [11] [12] Since NSE is present in neurons and not in glial cells, it is suggested to be a specific neuronal cell marker in contrast to S100B that is expressed in glial cells. 9, 13 Levels of NSE in relation to prognosis among patients with cardiac arrest with hypoxic ischemic encephalopathy were examined in a large cohort study. A cutoff level of 33 µg/l showed 100% specificity in predicting death or persistent unconsciousness after 1 month and NSE in combination with clinical parameters has been recommended as neurologic prognostication in this group of patients. 14 NSE has also shown to be a potential predictor of future vascular events and subclinical brain damage among asymptomatic hypertensive patients. 15 S100B is currently evaluated as a cerebral biomarker for traumatic brain injury. The extracerebral concentration is much lower than concentrations in neuronal tissue. 16 
BACKGROUND
There is evidence of cerebral involvement among women with preeclampsia. Levels of the cerebral biomarkers neuron-specific enolase (NSE) and S100B are elevated during pregnancy in women developing preeclampsia. It is although not known if these biomarkers return to normal range postpartum. The aim with this study was to compare levels of S100B and NSE during pregnancy and 1 year postpartum in women who have had preeclampsia to women with normal pregnancies.
METHODS
This study was a longitudinal study of cases (n = 53) with preeclampsia and controls (n = 58) consisted of normal pregnant women in matched gestational weeks. Plasma samples were collected at inclusion during pregnancy and 1 year postpartum. Plasma samples were analyzed for levels of S100B and NSE by enzyme-linked immunosorbent assays kits.
RESULTS
Levels of NSE and S100B in women with preeclampsia were higher during pregnancy than in women with normal pregnancies. One year postpartum, women who have had preeclampsia still had a higher median level of both NSE (5.07 vs. 4.28 µg/l, P < 0.05) and S100B (0.07 vs. 0.06 µg/l, P < 0.05) compared to women with previous normal pregnancies. High levels of NSE and S100B postpartum remained associated with previous preeclampsia after adjustment for confounding factors. Levels of NSE correlated to S100B during pregnancy and postpartum.
has been used as a prognostic biomarker both in minor and severe head injuries and so far proven to have best results in the field of minor head injuries. 17, 18 We have earlier shown that levels of S100B and NSE are elevated during pregnancy in women developing preeclampsia 19, 20 and that levels of S100B among women with preeclampsia correlate to presence of neurological symptoms in form of visual disturbances. 21 There are no previous data on what happens to levels of these biomarkers after pregnancy when preeclampsia no longer exists. Based on the evidence that women with former preeclampsia experience cognitive impairment and white matter lesions years after pregnancy, 5, 8 it is of great interest to examine how levels of these biomarkers behave 1 year postpartum in women who have had preeclampsia.
The aim with this study was to compare levels of S100B and NSE during pregnancy and 1 year postpartum in women who have had preeclampsia to women with normal pregnancies.
METHODS
The regional Ethics committee in Uppsala approved the study. Informed written consent was obtained from each woman in the study.
Study population
This study was designed as a longitudinal study. The material has been used in previous publications, regarding preeclampsia and arterial wall layer dimensions 22 and also regarding levels of S100B during pregnancy and association with CNS effects. 21 The method of recruitment and description of the study population is extensively described in these previous publications. 22 Cases (n = 53) were pregnant women with preeclampsia. They were included at the time when the diagnosis was confirmed. The definition of preeclampsia was newonset hypertension (≥140/90 mm Hg, observed on at least 2 separate measurements ≥6 hours apart), combined with proteinuria (≥2 units on a dipstick or a 24-hour urine sampling showing ≥300 mg albumin/24 hours) after gestational week 20. The controls (n = 58) were frequency matched according to gestational weeks ± 2 weeks and consisted of women with normal pregnancies defined as an uncomplicated progress throughout the whole pregnancy, with delivery after 37 weeks of gestation of an infant not small for gestational age (defined as birth weight more than 2 SD below mean birth weight for gestational age of the reference population). 23 At inclusion, maternal height, weight, and blood pressure were registered. Information about reproductive history and smoking habits, as well as pregnancy-related complications, gestational age at delivery, and birth weight of the infant was collected from the medical records.
At the postpartum examination, about 1 year after delivery, another blood sample was taken, blood pressure was measured and body mass index (BMI) was calculated. Three women in the preeclampsia group were pregnant again and 2 did not want to participate. Among the women with normal pregnancies, 4 women were pregnant. Thus, 48 women in the preeclampsia group and 54 women with normal pregnancies remained in the postpartum evaluation. Available blood samples were analyzed for NSE (41 women with preeclampsia and 51 women with normal pregnancies) and S100B (36 women with preeclampsia and 42 women with normal pregnancies).
Sample collection
A blood sample was collected in lithium/heparin containing tubes from each woman at inclusion and about 1 year postpartum. Mean time of sampling for women with preeclampsia was at 35 weeks + 1 day of gestation and for women with normal pregnancies at 34 weeks + 3 days of gestation. After collection, the blood samples were kept in room temperature for no longer than half an hour before being centrifuged for 10 minutes at 2,000 g. The plasma samples were separated and stored in new tubes at −70 °C until levels of NSE and S100B were analyzed. The mean storage time was less than 6 years.
Enzyme-linked immunosorbent assays
Plasma samples were analyzed for levels of S100B and NSE by enzyme-linked immunosorbent assays (ELISA). Commercially available kits (Sangtec 100 ELISA, Diasorin, MN and Humane Enolase 2 DENL20 ELISA, R&D Systems, Oxon, GB) were used and the tests were performed according to the manufacturer's recommendations. The interassay and intra-assay coefficients of variation were 3.3% and 7.7% for S100B and 5.0% and 2.1% for NSE, respectively. Limit of detection was 0.015 µg/l for S100B and 0.04 µg/l for NSE.
Statistics
Demographic and clinical characteristics were compared between women with preeclampsia and women with normal pregnancies by use of Student's t-test and chi-square tests. Levels of NSE and S100B were compared between women with preeclampsia and women with normal pregnancies by use of Mann-Whitney U-test. NSE and S100B levels below the detection limits of the ELISA were recorded as zero. Changes in levels of NSE and S100B from pregnancy to postpartum within individuals in their respective group were calculated by Wilcoxon signed ranked test. Correlation between levels of NSE and S100B within individuals during pregnancy and postpartum was measured with Spearman's rho and correlation coefficients were used to estimate degree of correlation. To adjust the associations between preeclampsia and postpartum levels of NSE and S100B for potential confounding factors, we used linear regression and included women's age, parity, postpartum BMI, and days since delivery as continuous variables in the model. Levels of NSE and S100B were logarithmic transformed due to non-normality. All significance tests were 2-tailed and the level of significance was P < 0.05. Statistical analysis was performed using SPSS, version 23.0 (SPSS, PASW statistics) for MAC software package.
RESULTS

Background characteristics
Maternal characteristics and pregnancy outcome of women with preeclampsia and women with normal pregnancies are presented in Table 1 . At first antenatal visit, women who developed preeclampsia did not differ from controls in terms of age or smoking habit, but they were more often nulliparous and had higher BMI and blood pressure. At, inclusion, the mean blood pressure in the preeclampsia group was 146/91 mm Hg and at delivery, 85% of the women with preeclampsia had antihypertensive medication. Women with preeclampsia and women with normal pregnancies were matched for gestational age at time of inclusion but women with preeclampsia had, as expected, a shorter gestational length at delivery and delivered infants with lower birth weight than women with normal pregnancies.
At the control about 1 year postpartum, women with previous preeclampsia still had a higher blood pressure and a higher BMI in contrast to women with previous normal pregnancies. The time elapsed since delivery did not differ significantly between groups (Table 2) .
Plasma levels of NSE
Median plasma level of NSE in women with preeclampsia was higher during pregnancy than in women with Values are presented as mean ± SD; Student's t-test. Plasma levels of NSE and S100B are presented as medians with interquartile range. Abbreviations: BMI, body mass index; BP, blood pressure; MAP, mean arterial pressure; n, number; NS, not significant; NSE, neuron-specific enolase.
normal pregnancies (4.47 vs. 3.04 µg/l; P < 0.001). Among women with preeclampsia, 1 year postpartum, the median plasma level of NSE was at a similar level as during pregnancy (5.07 vs. 4.47 µg/l; P = 0.25). In women with normal pregnancies, levels of NSE were higher 1 year postpartum compared to levels during pregnancy (medians 4.28 vs. 3.04 µg/l; P < 0.05). One year postpartum, women who have had preeclampsia still had higher levels of NSE compared to women with previous normal pregnancies, (medians 5.07 vs. 4.28 µg/l; P < 0.05) ( Figure 1 and Table 2 ). When adjusting for common confounding factors; age, parity, BMI, and days since delivery, higher levels of NSE 1 year postpartum were still independently associated with previous preeclampsia (P < 0.001).
Plasma levels of S100B
As shown earlier, levels of S100B are higher during pregnancy in women with preeclampsia compared to women with normal pregnancies. 21 One year postpartum, median levels of S100B have declined among women who have had preeclampsia (0.12 vs. 0.07 µg/l; P < 0.001). In women with normal pregnancies, levels of S100B also had declined 1 year postpartum but to a lesser extent (medians 0.07 vs. 0.06 µg/l; P < 0.05). One year postpartum, women with previous preeclampsia still experienced higher levels of S100B in contrast to women with previous normal pregnancies (medians 0.07 vs. 0.06 µg/l, P < 0.05) (Figure 2 ). When adjusting for common confounding factors; age, parity, BMI, and days since delivery, higher levels of S100B at 1 year postpartum were still independently associated with previous preeclampsia (P < 0.01).
Correlation between NSE and S100B
Levels of NSE and S100B correlated during pregnancy (correlation coefficient (r s ) = 0.29, P < 0.01) and postpartum (r s = 0.42, P < 0.001). When we stratified the women into those with preeclampsia and those with normal pregnancies, levels of NSE and S100B had a borderline significant correlation during pregnancy (r s = 0.26, P = 0.06) and a significant correlation postpartum (r s = 0.40, P < 0.01) in women with preeclampsia. In women with normal pregnancies, levels of NSE and S100B did not correlate during pregnancy or postpartum (r s = 0.12 and 0.20, P = 0.38 and 0.21, respectively).
DISCUSSION
This study shows that 1 year postpartum, both levels of NSE and S100B are higher in women who have had preeclampsia compared to women with previous normal pregnancies. Women who have had preeclampsia or eclampsia without other acute complications have an increased risk of persistent cognitive impairment for months or even years after the pregnancy 24 and women with previous hypertensive disease show brain atrophy and cognitive impairment decades after the pregnancy. 8 It is also well known that women who have had preeclampsia have a higher risk of The most extreme value of S100B during pregnancy is withdrawn from the figure but included in the statistical analysis. Levels of S100B during pregnancy are previously published. 21 The 2 boxplots to the left are levels of S100B during pregnancy and to the right about 1 year postpartum. cardiovascular disease. [25] [26] [27] This finding might indicate that the integrity of the blood vessel wall and blood brain barrier (BBB) in women with former preeclampsia are still affected 1 year postpartum. The findings in this study also confirms that levels of NSE are elevated among women with preeclampsia in contrast to women with normal pregnancies. 19 The levels of NSE during preeclampsia are in the same range as in our previously published longitudinal study. 19 In this present study, we showed that levels of NSE are higher postpartum in women who have had preeclampsia, compared to women with previous normal pregnancies. Levels of NSE remain on the same level during and after pregnancy in women who have had preeclampsia whereas they increase postpartum in women with normal pregnancies. In normal pregnancy, NSE levels are highest in early pregnancy but decline throughout pregnancy. 19 These previous results together with present results indicate that levels of NSE are higher in normal nonpregnant and early pregnant states compared to the second and third trimesters of pregnancy. Unknown factors lead to a decline in the levels of NSE during normal pregnancy, whereas women who develop preeclampsia experience higher levels both in early and late pregnancy and also 1 year postpartum. Since NSE is a cerebral biomarker, we hypothesize that the differences in NSE levels between women with normal pregnancies and women with preeclampsia during pregnancy and also postpartum are due to cerebral involvement. One possible mechanism of action could be a potential leakage through the BBB among women with preeclampsia though this cannot be determined in this material.
During pregnancy, there is a greater variation in S100B levels between subjects than it is postpartum, both in women with normal pregnancies and in women with preeclampsia. In women with preeclampsia, the variation is even greater and also remains greater postpartum compared to healthy controls. Since there is a greater interindividual variation of S100B during pregnancy compared to postpartum, there is a need for individual evaluation of S100B levels in women with preeclampsia.
Our results indicate higher levels of S100B during pregnancy than postpartum, especially among women with preeclampsia. Preeclampsia is associated with endothelial dysfunction, 28 but the endothelium is of a milder degree also affected in normal pregnancy. 28 We hypothesize that the BBB is affected during the pregnancy and S100B crosses the BBB from the CNS to the peripheral circulation. This is supported by an earlier study where plasma from women with preeclampsia increased BBB permeability in a rat model. 29 Postpartum the endothelium recovers, but our finding of higher S100B levels among women with former preeclampsia compared to those with former normal pregnancy indicates a persistent endothelial dysfunction with affected BBB after preeclampsia. However, the difference between the groups is small and the clinical implication uncertain.
The 2 biomarkers correlate both during pregnancy and postpartum, but only in women with preeclampsia. This might reflect the cerebral origin of the biomarkers during preeclampsia. The loss of correlation between NSE and S100B in women with normal pregnancies might reflect a noncerebral origin since the biomarkers are also secreted from different sources outside the CNS. Since NSE and S100B reflect different origins in the brain, they could potentially be used in combination in a prediction model for cerebral involvement among women with preeclampsia.
The strengths with this study are that it is a prospective study with well-defined diagnostic criteria for preeclampsia. The ELISA kits used are commercially available and have been used in similar studies for cerebral pathology in other fields. There can be a great variation between different manufacturers but in our material, the same manufacturers were used for the samples both during and after pregnancy. The levels of the cerebral biomarkers are measured during pregnancy and 1 year postpartum in the same individuals, which make the results reliable and exclude the risk of interindividual variation. The drop-out rate at the follow up 1 year postpartum was very low (5/53) and out of these, 3 women were excluded because of a new pregnancy.
The limitations with the study are that there are confounding sources that contribute to the plasma levels of these biomarkers. For NSE, alternative sources are red blood cells, 30 platelets, and the diffuse neuroendocrine system cells. [10] [11] [12] For S100B, alternative sources are melanocytes, chondrocytes, adipocytes, skeletal myofibres and associated satellite cells, some dendritic cells and lymphocyte populations, and a few other cell types. 31 In this material, it is not possible to determine if the difference between levels of these biomarkers are due to cerebral involvement in preeclampsia or a result of augmented excretion from alternative sources. Since S100B and NSE are validated as cerebral biomarkers in other types of populations such as in traumatic brain injury and cardiac arrest, this would argue for CNS as the source for the elevated levels also among women with preeclampsia. Earlier findings, at least concerning S100B, suggest that the extracerebral contribution in cases of head trauma is negligible. 32 NSE and S100B 1 year postpartum remained independently associated with previous preeclampsia after adjustment for parity, age, days since delivery, and BMI. Unfortunately, we were not able to adjust for hemolysis. Though, in our earlier material, NSE was still a significant risk factor for preeclampsia after adjusting for lactate dehydrogenase as a proxy for hemolysis. 19 In conclusion, this study shows that levels of the cerebral biomarkers NSE and S100B are still elevated 1 year postpartum in women who have had preeclampsia in contrast to women who have had normal pregnancies. The biomarkers correlate in women with preeclampsia but not in women with normal pregnancies. The source of the augmented excretion cannot be determined in this material but we hypothesize that there might be a persistent cerebral involvement among women with preeclampsia even 1 year postpartum. These findings need to be confirmed in a larger prospective study with longitudinal measurements of NSE and S100B and also in correlation to cerebral signs and symptoms.
